Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
Many clinical trials and meta-analyses have shown that subcutaneous injections of LMWH are ... developed and evaluated for the prophylaxis and treatment of VTE. Idraparinux, a long-acting ...
Exclusion criteria for VTE prophylaxis included coagulopathy, bleeding disorder, spinal epidural hematoma, hepatic failure, platelets less than or equal to 100×10 3 /μL, estimated creatinine ...
Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for ...
The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was better than regular prophylaxis injections with Factor VIII (FVIII) replacement therapies at ...
“The subcutaneous formulation of amivantamab offers an improved treatment experience for patients, reducing administration time from hours to minutes and substantially lowering rates of ...
Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
VTE events with and without VTE prophylaxis during NACT. Characteristics No VTE Prophylaxis N=184 (63.4%) VTE Prophylaxis N=106 (36.5%) p-value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback